Melatonin Supports Non Surgical Periodontal Treatment in Patients With Type 2 Diabetes and Periodontitis
Diabetes Mellitus, Periodontitis, Melatonin
About this trial
This is an interventional treatment trial for Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria: According to the WHO, in individuals in the young age category (18-65 years) Periodontitis diagnosed patients, "stage 3/4 periodontitis" was determined according to the current periodontal disease and condition classification as the diagnostic criterion for periodontitis Diabetic patients, our diagnostic criteria for Type 2 DM was fasting plasma glucose level greater than 126 mg/dl and glycosylated hemoglobin level (HbA1c) greater than 6.5%. Exclusion Criteria: Smoke, use antibiotics, anti-inflammatory and antioxidant drugs in the last 6 months Work night shifts Pregnancy and lactation Cancer and autoimmune diseases Kidney disease Periodontal treatment in the last 6 months Obese patients (In Europe, obesity is defined as a body-mass index of more than 30 kg/m2 and a waist circumference of more than 88 cm in women and 102 cm in men)
Sites / Locations
- Yagmur Sarac Gul
Arms of the Study
Arm 1
Arm 2
No Intervention
Active Comparator
fmSRP
fmSRP-mel
27 patients with diabetic periodontitis underwent full mouth scaling and root planning (fmSRP) alone
28 patients with diabetic periodontitis were administered systemic melatonin tablets (6 mg daily, for 30 days) immediately after fmSRP.